Alaunos posted a net loss of $1.9 million for the six months ended June 30, 2026, with no royalty revenue.
Research and development expense climbed 53% to $814,000, driven by higher stock-based compensation, salaries and consulting tied to its obesity program.
General and administrative expense fell 28% to $1.15 million on lower salaries, insurance, filing, banking, legal and travel costs following downsized operations.
Cash and equivalents totaled $120,000 at June 30, 2026; monthly cash burn runs about $210,000, with funding expected into Q3 2026.
Lead preclinical candidate ALN1003 advanced on DIO mouse data; Nasdaq flagged a stockholders’ equity shortfall versus the $2.5 million requirement.
TCRT•
